XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Merger with Sesen Bio (Details) - USD ($)
$ in Thousands
Mar. 07, 2023
Mar. 31, 2023
Dec. 31, 2022
Merger with Sesen Bio      
Entity common stock, shares outstanding immediately after merger   40,254,666 2,217,737
Cash and cash equivalents $ 37,873    
Marketable securities 44,588    
Prepaid expenses and other assets 1,316    
Restricted cash 30    
Accounts payable and accrued expenses (3,499)    
Total net assets acquired 80,308    
Less: Transaction costs (8,264)    
Total net assets acquired less transaction costs 72,044    
Carisma Therapeutics Inc.      
Merger with Sesen Bio      
Severance and personnel costs paid $ 4,600    
CARISMA Therapeutics Inc, Legacy, Stockholders | Carisma Therapeutics Inc.      
Merger with Sesen Bio      
Business acquisition percentage of voting interests acquired 74.20%    
Entity common stock, shares outstanding immediately after merger 40,254,666